scholarly journals Influence of sodium valproate treatment on body mass and insulin resistance parameters in children with epilepsy

2020 ◽  
pp. 84-84
Author(s):  
Aleksandar Dimitrijevic ◽  
Radan Stojanovic ◽  
Dragana Bogicevic ◽  
Vesna Mitic ◽  
Dimitrije Nikolic
Keyword(s):  
Valproic Acid ◽  
Weight Gain ◽  
Sodium Valproate ◽  
Glucose Homeostasis ◽  
Acid Treatment ◽  
Statistical Significance ◽  
Insulin Level ◽  
Serum Glucose ◽  
Drug Discontinuation ◽  
Healthy Children

Introduction/Objective. One of the main side-effects in patients undergoing valproic acid treatment is weight gain. Weight gain might be the reason for drug discontinuation, especially in adolescent girls, and it has to be considered also before introducing the drug. The main goal of our study is to investigate a possible influence of antiepileptic therapy with sodium valproate on weight and glucose homeostasis in pediatric patients with epilepsy. Methods. The investigation included a total of 49 healthy children with recently diagnosed epilepsy. We measured height, weight and serum 12-hour overnight fasting glucose and insulin level before initiation and after 6- and 12-month valproic acid treatment period. The BMI and HOMA indexes were calculated for each patient and correlated after the initiation of therapy and after 6 and 12 months of therapy. Results. We found that children significantly gained weight with statistical significance (p<0.01) even after 6 months of therapy with a significant glucose metabolism change and statistical difference in average serum glucose and insulin levels (p<0.05). Conclusion. Our results show that a 12-month treatment with valproic acid in children with epilepsy has a great impact on weight gain and glucose homeostasis and metabolism. We strongly recommend that all children with recently diagnosed epilepsy at the initiation of valproate therapy should be closely monitored on a 6-month basis. Consultation of nutritionist is advised especially in children with preexisting problem with body weight.

scholarly journals VALPROIC ACID AS A REFERENCE SUBSTANCE FOR THE STUDY OF THE MOLECULAR-GENETIC MECHANISM OF OBESOGENITY OF ENDOCRINE DISRUPTERS

2019 ◽  
Vol 96 (5) ◽  
pp. 422-426 ◽  
Author(s):  
M. G. Aksenova ◽  
O. O. Sinitsyna ◽  
A. V. Kirillov ◽  
O. B. Kozlova ◽  
S. G. Burd
Keyword(s):  
Fatty Acids ◽  
Valproic Acid ◽  
Weight Gain ◽  
Molecular Genetic ◽  
Insulin Level ◽  
Genetic Mechanism ◽  
Medium Chain ◽  
Medium Chain Fatty Acids ◽  
Pparγ Gene ◽  
Chain Fatty Acids

Perfluorooctanoic acid (PFOA) and its derivatives are recognized as obesogens. Clinically used valproic acid (VPA) as a drug is structurally similar to PFOA. The objective of the investigation was to study the molecular-genetic mechanism of the weight gain by patients taking the VPA drugs and correlation with candidate genes involved in the metabolism of medium chain fatty acids. Weight and basal insulin level were evaluated in 238 patients both before and after 12 months of VPA treatment. Genotyping of SNPs rs1801282, C>G (Pro12Ala) gene PPARγ and rs1799883, G>A (Ala54Thr) gene FABP2 were performed with TaqMan Real-Time PCR Assay. Women who gained weight were genotyped «СС» for the rs1801282 PPARγ gene and appeared to have significantly higher insulin level (26.3±1.7 uU/ml) as compared to women with the same genotype and without weight gain (14.9±3.1 uU/ml). Similarly, men who gained weight and were genotyped «СС» for the rs1801282 PPARγ gene, showed significantly higher insulin level (25.4±1.8 uU/ml) as compared to men with the same genotype and without weight gain (13.,3±2.9 uU/ml). Women who gained weight and were genotyped «AA» or «AG» for the rs1799883 FABP2 gene had significantly higher insulin level (32.1±1.7 uU/ml) as compared to women with the same genotype and without weight gain (17.1±3.2 uU/ml). No correlation of insulin levels with weight gain and genotypes were identified for men. Obesogens, structurally similar to the medium chain fatty acids (in particular PFOA and analogues), can affect weight gain through the development of insulin resistance.

Effect of valproic acid treatment on body composition, leptin and soluble leptin receptor in epileptic children

2006 ◽  
Vol 37 (06) ◽  
Author(s):  
M Rauchenzauner ◽  
E Haberlandt ◽  
S Scholl-Bürgi ◽  
D Karall ◽  
E Schönherr ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Body Composition ◽  
Acid Treatment ◽  
Leptin Receptor ◽  
Soluble Leptin Receptor ◽  
Epileptic Children

scholarly journals Higher Caloric Refeeding Is Safe in Hospitalised Adolescent Patients with Restrictive Eating Disorders

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Elizabeth K. Parker ◽  
Sahrish S. Faruquie ◽  
Gail Anderson ◽  
Linette Gomes ◽  
Andrew Kennedy ◽  
...  
Keyword(s):  
Eating Disorders ◽  
Weight Gain ◽  
Statistical Significance ◽  
Caloric Intake ◽  
Tube Feeding ◽  
Retrospective Chart Review ◽  
Refeeding Syndrome ◽  
Restrictive Eating ◽  
Weight Restoration ◽  
The Mean

Introduction. This study examines weight gain and assesses complications associated with refeeding hospitalised adolescents with restrictive eating disorders (EDs) prescribed initial calories above current recommendations.Methods. Patients admitted to an adolescent ED structured “rapid refeeding” program for >48 hours and receiving ≥2400 kcal/day were included in a 3-year retrospective chart review.Results. The mean (SD) age of the 162 adolescents was 16.7 years (0.9), admission % median BMI was 80.1% (10.2), and discharge % median BMI was 93.1% (7.0). The mean (SD) starting caloric intake was 2611.7 kcal/day (261.5) equating to 58.4 kcal/kg (10.2). Most patients (92.6%) were treated with nasogastric tube feeding. The mean (SD) length of stay was 3.6 weeks (1.9), and average weekly weight gain was 2.1 kg (0.8). No patients developed cardiac signs of RFS or delirium; complications included 4% peripheral oedema, 1% hypophosphatemia (<0.75 mmol/L), 7% hypomagnesaemia (<0.70 mmol/L), and 2% hypokalaemia (<3.2 mmol/L). Caloric prescription on admission was associated with developing oedema (95% CI 1.001 to 1.047;p=0.039). No statistical significance was found between electrolytes and calories provided during refeeding.Conclusion. A rapid refeeding protocol with the inclusion of phosphate supplementation can safely achieve rapid weight restoration without increased complications associated with refeeding syndrome.

Thyroid Functions in Children on Levetiracetam or Valproic Acid Therapy

2020 ◽  
Author(s):  
Elif Karatoprak ◽  
Samet Paksoy
Keyword(s):  
Valproic Acid ◽  
Subclinical Hypothyroidism ◽  
Control Group ◽  
Thyroid Function Tests ◽  
Healthy Children ◽  
Control Groups ◽  
Acid Therapy ◽  
Significant Difference ◽  
And Control ◽  
Tsh Levels

AbstractThe aim of this study was to investigate the thyroid functions in children receiving levetiracetam or valproate monotherapy. We retrospectively reviewed the records of children with controlled epilepsy receiving valproic acid (VPA group) or levetiracetam monotherapy (LEV group) for at least 6 months. Free thyroxine 4 levels (fT4) and thyroid stimulating hormone (TSH) levels were compared between VPA group, LEV group, and age- and gender-matched healthy children (control group). A total of 190 children were included in the study: 63 were in the VPA, 60 in the LEV, and 67 in the control group. Although there was no significant difference regarding average fT4 levels, higher TSH levels were found in the VPA group when compared with the LEV and control groups (p < 0.001 and p < 0.001, respectively). There was no significant difference in terms of fT4 and TSH values in the LEV group when compared with the control group (p = 0.56 and p = 0.61, respectively). Subclinical hypothyroidism (defined as a TSH level above 5 uIU/mL with a normal fT4 level was detected in 16% of patients in the VPA group, none in the LEV and control groups. Our study found that VPA therapy is associated with an increased risk of subclinical hypothyroidism while LEV had no effect on thyroid function tests.

Association between early antibiotic exposure and risk of childhood weight gain and obesity: a systematic review and meta-analysis

2019 ◽  
Vol 32 (5) ◽  
pp. 439-445 ◽  
Author(s):  
Mohammad Aghaali ◽  
Seyed Saeed Hashemi-Nazari
Keyword(s):  
Systematic Review ◽  
Weight Gain ◽  
Childhood Obesity ◽  
Early Life ◽  
Meta Analysis ◽  
Healthy Children ◽  
Antibiotic Exposure ◽  
Statistical Estimates ◽  
Childhood Weight

Abstract Background Recent studies have shown that antibiotic exposure during infancy is associated with increased body mass in healthy children. This study was performed to investigate the association between early-life antibiotic exposure and risk of childhood obesity. Methods A systematic review and meta-analysis was performed to comprehensively and quantitatively determine the association between early antibiotic exposure and risk of childhood obesity. Various databases such as PubMed, Embase, Scopus, Web of Science, ProQuest, Cochrane and Google Scholar were searched. A random-effects meta-analysis was performed to pool the statistical estimates. Additionally, a subgroup analysis was performed based on the time of follow-up. Results Nineteen studies involving at least 671,681 participants were finally included. Antibiotic exposure in early life was significantly associated with risk of childhood weight gain and obesity (odds ratio [OR]: 1.05, 95% confidence interval [CI]: 1.04–1.06). Conclusions Antibiotic exposure in early life significantly increases the risk of childhood weight gain and obesity.

MO843PREVALENCE AND MANAGEMENT OF HYPERTENSION IN HEMODIALYSIS PATIENTS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Ali AlSahow ◽  
Anas Alyousef ◽  
Bassam Alhelal ◽  
Heba AlRajab ◽  
Yousif Bahbahani ◽  
...  
Keyword(s):  
Weight Gain ◽  
Fluid Intake ◽  
Salt Intake ◽  
Statistical Significance ◽  
Dry Weight ◽  
Weekly Schedule ◽  
Interdialytic Weight Gain ◽  
High Salt Intake ◽  
Number Of Patients ◽  
High Calcium

Abstract Background and Aims Hypertension (HTN) is common in hemodialysis (HD) patients & diagnosed by pre-dialysis BP &gt;140/90 mmHg. Causes include high salt intake, volume overload, & loss of residual kidney function. Therapy includes achieving correct dry weight with each session, restricting interdialytic sodium & fluid intake & medications. We review its prevalence, factors associated with it & its management in our patients. Method Demographics, HD prescription & medications data collected for patients from 5 dialysis centers. Results A total of 1585 files reviewed. Males were 51.8% & mean age was 59. Mean age significantly higher for females (61 vs 57). ESKD cause was DM in 51% & HTN in 35%. However, of files reviewed, adequate data on comorbidities in 1390 patients (table 1), 69% had DM, 92% had HTN, 47% had CVD & 31% had BMI &gt; 25 (which was significantly more frequent in females). HTN was more likely in older patients, diabetics & females with odds of HTN in females nearly twice the odds of HTN in males & odds of HTN with DM is 2.27 times odds of HTN without DM & one-year increase in age would increase odds of HTN by nearly 4%. Mean pre-HD BP for those with HTN was 143/76 mmHg & for those without HTN was 136/75 mmHg. HD frequency was thrice weekly in 94% & HD duration was &gt; 3.5 hours in only 77% of patients. HDF used in 81.5%. Mean interdialytic weight gain (IDWG) was 2.8 kg, with no difference according to gender or presence of DM or HTN (Table 2). Higher IDWG associated with age &lt; 65, Calcium bath of 1.75 & Sodium bath &gt; 138 with 0.638 kg higher IDWG with calcium of 1.75 compared to calcium of 1.25. Higher IDWG was associated with higher BP. Mean volume of fluid removed per session was 2.74, which was less than mean IDWG, with no difference according to gender or DM, however, it was higher in the higher dialysate sodium group, & lower in the shorter session group (with trend towards statistical significance). CCB used to treat HTN in 62% followed by βB in 52%. Number of patients with HTN on 1 drug 21%, 2 drugs 27%, 3 drugs 23%, ≥ 4 drugs 20% & 9% missing data. Number of antihypertensives did not correlate with IDWG. Conclusion Interdialytic weight gain in our HD patients is excessive & contributing to HTN. Patients must restrict salt & fluid intake & dialysis centers must regularly & frequently assess dry weight, ensure thrice weekly schedule & 4 hours per session are met, so excess fluid is completely removed. Also, high sodium & high calcium baths need to be avoided.

Effect of Valproic Acid Treatment on Spike-Wave Discharge Patterns during Sleep and Wakefulness

1983 ◽  
Vol 10 (1) ◽  
pp. 56-59 ◽  
Author(s):  
W. Burr ◽  
H. Stefan ◽  
C. Kuhnen ◽  
F. Hoffmann ◽  
H. Penin
Keyword(s):  
Valproic Acid ◽  
Acid Treatment ◽  
Discharge Patterns ◽  
Wave Discharge ◽  
Spike Wave

scholarly journals Tetrahydro iso-Alpha Acids from Hops Improve Glucose Homeostasis and Reduce Body Weight Gain and Metabolic Endotoxemia in High-Fat Diet-Fed Mice

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e33858 ◽  
Author(s):  
Amandine Everard ◽  
Lucie Geurts ◽  
Marie Van Roye ◽  
Nathalie M. Delzenne ◽  
Patrice D. Cani
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Glucose Homeostasis ◽  
High Fat Diet ◽  
Body Weight Gain ◽  
High Fat ◽  
Reduce Body Weight ◽  
Metabolic Endotoxemia

Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children

2008 ◽  
Vol 80 (2-3) ◽  
pp. 142-149 ◽  
Author(s):  
M. Rauchenzauner ◽  
E. Haberlandt ◽  
S. Scholl-Bürgi ◽  
D. Karall ◽  
E. Schoenherr ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Body Composition ◽  
Acid Treatment ◽  
Leptin Receptor ◽  
Soluble Leptin Receptor ◽  
Epileptic Children
Sign in / Sign up

Export Citation Format

Share Document